CANSINO BIOLOGICS INC. (CanSinoBIO) is China’s
dynamic bio-tech leader blazing new paths in R&D,
manufacturing and commercialisation of vaccine
products for human use. Founded in the Tianjin
Economic and Technological Development Area (TEDA)
in 2009, Founders of CanSinoBIO formed a superb
team of scientists and managers who had previously
held senior management and technical positions at many of the world leading
pharmaceutical companies. To date, the management team has boasted a proven
track record of success in new drug discovery, development and commercialisation.
In addition, CanSinoBIO’s scientific advisory board is made up of internationally
recognised senior executives and leading members of academia who provide unique
and complementary insights to guide the company’s growth.
Equipped with the latest cutting-edge scientific know-how and technology, CanSinoBIO
is on a relentless quest to develop high value, high quality vaccines for China and other
emerging countries at an affordable cost.
We want to lead and foster the Chinese vaccine industry to become a major contributor
to global public health. CanSinoBIO’s expertise is indeed invaluable for closing the gap
in quality and techniques between the Chinese vaccine industry and world vaccine leaders.
Currently, we at CanSinoBIO are developing ground-breaking products that are in high
demand but lack sufficient supply or quality. These include products such as quadrivalence
(ACYW135) meningococcal conjugate vaccine, pneumococcal polysaccharide and conjugate
vaccines as well as a DTcP-based combo and other items. At the same time, we are also
dedicating our efforts to new vaccine development like recombinant adenovirus vector-based
tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.
Vaccination is an essential part of effective disease control and prevention. “Our ultimate
goal is to make top quality vaccines accessible to people all over the world.”
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2